LT2646557T - Būdas, skirtas ląstelinei rnr ekspresijai - Google Patents

Būdas, skirtas ląstelinei rnr ekspresijai

Info

Publication number
LT2646557T
LT2646557T LTEP11791447.3T LT11791447T LT2646557T LT 2646557 T LT2646557 T LT 2646557T LT 11791447 T LT11791447 T LT 11791447T LT 2646557 T LT2646557 T LT 2646557T
Authority
LT
Lithuania
Prior art keywords
rna expression
cellular rna
cellular
expression
rna
Prior art date
Application number
LTEP11791447.3T
Other languages
English (en)
Inventor
Ugur Sahin
Tim Beissert
Marco Poleganov
Stephanie Herz
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Translationale Onkologie An Der Universitätsmedizin Der Jgu Mainz Ggmbh (Tron)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Translationale Onkologie An Der Universitätsmedizin Der Jgu Mainz Ggmbh (Tron) filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of LT2646557T publication Critical patent/LT2646557T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases [EC 2.]
    • C12N2501/727Kinases (EC 2.7.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LTEP11791447.3T 2010-12-03 2011-12-02 Būdas, skirtas ląstelinei rnr ekspresijai LT2646557T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/007362 WO2012072096A1 (en) 2010-12-03 2010-12-03 Method for cellular rna expression
PCT/EP2011/006061 WO2012072269A1 (en) 2010-12-03 2011-12-02 Method for cellular rna expression

Publications (1)

Publication Number Publication Date
LT2646557T true LT2646557T (lt) 2017-10-10

Family

ID=44202296

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11791447.3T LT2646557T (lt) 2010-12-03 2011-12-02 Būdas, skirtas ląstelinei rnr ekspresijai

Country Status (10)

Country Link
US (1) US20140030808A1 (lt)
JP (2) JP6131433B2 (lt)
AU (1) AU2011335428B2 (lt)
CA (1) CA2819522C (lt)
DK (1) DK2646557T3 (lt)
ES (1) ES2640875T3 (lt)
HU (1) HUE034558T2 (lt)
LT (1) LT2646557T (lt)
PT (1) PT2646557T (lt)
WO (2) WO2012072096A1 (lt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS56419B1 (sr) * 2010-12-03 2018-01-31 Biontech Rna Pharmaceuticals Gmbh Postupak za ćelijsku ekspresiju rnk
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
AU2013343864B2 (en) 2012-11-09 2019-04-04 BioNTech SE Method for cellular RNA expression
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
EP3750993B1 (en) 2014-07-11 2023-12-27 Celgene Corporation Methods of improving vector transduction efficiency into t lymphocytes
KR101668074B1 (ko) * 2015-02-12 2016-10-21 전북대학교산학협력단 Pkr 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물
CN107592807B (zh) 2015-02-26 2022-04-15 Sio2医药产品公司 具有耐划伤且抗静电的涂层的环烯烃聚合物容器
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
HRP20230050T1 (hr) 2016-05-18 2023-03-03 Modernatx, Inc. Polinukleotidi koji kodiraju interleukin-12 (il12) i njihova upotreba
KR20190017985A (ko) * 2016-06-14 2019-02-20 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직, 및 장기
US20190382832A1 (en) * 2017-01-12 2019-12-19 University Of Central Florida Research Foundation, Inc. High-throughput and single nucleotide resolution techniques for the determination of rna post-transcriptional modifications
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3982497A (en) * 1996-07-30 1998-02-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner
IL126757A0 (en) * 1998-09-07 1999-08-17 Yissum Res Dev Co Regulation of gene expression through manipulation of mRNA splicing and its uses
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
EP2072618A1 (en) * 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
WO2010124143A1 (en) * 2009-04-23 2010-10-28 Nevada Cancer Institute Reprogramming of somatic cells with purified proteins

Also Published As

Publication number Publication date
US20140030808A1 (en) 2014-01-30
PT2646557T (pt) 2017-10-03
AU2011335428A1 (en) 2013-05-30
DK2646557T3 (en) 2017-10-02
AU2011335428B2 (en) 2016-12-22
CA2819522C (en) 2019-07-16
JP2013545469A (ja) 2013-12-26
WO2012072269A1 (en) 2012-06-07
JP2017079749A (ja) 2017-05-18
CA2819522A1 (en) 2012-06-07
WO2012072096A8 (en) 2012-07-26
HUE034558T2 (en) 2018-02-28
ES2640875T3 (es) 2017-11-07
WO2012072096A1 (en) 2012-06-07
JP6131433B2 (ja) 2017-05-24

Similar Documents

Publication Publication Date Title
LT2646557T (lt) Būdas, skirtas ląstelinei rnr ekspresijai
EP2552873A4 (en) PREPARATION FOR HEXAFLUOR-2-BUTEN
GB201001833D0 (en) Method
GB201007353D0 (en) Method
GB201007354D0 (en) Method
HU1000330D0 (en) Novel method
GB201011513D0 (en) Method
GB201004759D0 (en) Method
EP2619169A4 (en) PROCESS FOR THE PREPARATION OF BROMOURÉE
EP2620498A4 (en) PROCESS FOR THE ACQUISITION OF SMALL RNA
EP2594552A4 (en) PROCESS FOR PRODUCING RAMALINE
GB201012148D0 (en) Method
GB201006306D0 (en) Method
GB201010855D0 (en) Method
GB201012784D0 (en) Method
EP2589656A4 (en) GENEINSETZUNGSVERFAHREN
GB201007207D0 (en) Method
PL2646557T3 (pl) Sposób ekspresji RNA w komórce
GB201017003D0 (en) Method
GB201007522D0 (en) Method
PL395545A1 (pl) Sposób otrzymywania modyfikowanych oligosilseskwioksanów klatkowych
PL395546A1 (pl) Sposób otrzymywania modyfikowanych oligosilseskwioksanów klatkowych
IL225307A (en) A method of preparing bromine urine
GB201016857D0 (en) Culture method
FI20105259A0 (fi) Menetelmä langattomiin sarjaliikenneyhteyksiin